Prostate-specific antigen – T cell receptor recognition complex (PSA-TCR complex)

The Prostate-specific antigen (PSA) – T cell receptor (TCR) recognition complex is a specialized molecular assembly formed when a T cell receptor binds to a PSA-derived peptide presented by a Major Histocompatibility Complex (MHC) molecule, typically HLA-A*02:01 [1][2]. PSA, also known as Kallikrein-3 (KLK3), is a serine protease primarily produced by the prostate gland and is significantly overexpressed in nearly all prostate cancers, making its peptide-MHC complexes ideal targets for immunotherapy [1][4]. This complex is the fundamental unit of recognition for TCR-engineered T cell (TCR-T) therapies and cancer vaccines, which aim to redirect the patient's immune system to identify and destroy malignant cells [3][5]. Upon successful binding of the TCR to the PSA-MHC complex, a signaling cascade is initiated within the T cell, leading to the release of cytotoxic granules such as perforin and granzymes that induce apoptosis in the target prostate cancer cell [5]. While PSA is highly tissue-specific, its presence in normal prostatic tissue means that therapies targeting this complex may lead to localized inflammation or prostatitis, though this is generally considered a manageable side effect in the context of advanced malignancy [3]. Current clinical efforts focusing on this complex include the development of viral vector vaccines like PROSTVAC and adoptive cell transfers using high-affinity TCRs [3][4].

Other names

PSA-MHC-TCR complexKallikrein-3 peptide-HLA complexKLK3-TCR recognition complexPSA-HLA-A*02:01 complexProstate-specific antigen – MHC class I complex

T-cell mediated cytotoxicity, Antigen recognition, Immune activation, Targeted cell lysis